Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Phase 2a Multi-site, Randomized, Double-blind, Dose Escalated, Placebo Controlled Biomarker Study to Determine the Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI (Mild Cognitive Impairment) or Mild Dementia Due to Alzheimer's Disease (AD) Aged 50 to 85 Years
Authors not listed
Arctic Therapeutics · 2025
Abstract
The study aims to measure safety, tolerability and biomarker-based efficacy of NPI-001 (AT-001) in Subjects with MCI or Alzheimer's Disease (AD).
In the study participants receive increasing dose of active treatment (250mg vs 500mg vs 750mg) or matched placebo in the form of tablets BID.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-02 MST
Cite this
APA
Anonymous. (2025). A Phase 2a Multi-site, Randomized, Double-blind, Dose Escalated, Placebo Controlled Biomarker Study to Determine the Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI (Mild Cognitive Impairment) or Mild Dementia Due to Alzheimer's Disease (AD) Aged 50 to 85 Years. <em>Arctic Therapeutics</em>. https://clinicaltrials.gov/study/NCT07741526
Vancouver
Anonymous. A Phase 2a Multi-site, Randomized, Double-blind, Dose Escalated, Placebo Controlled Biomarker Study to Determine the Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI (Mild Cognitive Impairment) or Mild Dementia Due to Alzheimer's Disease (AD) Aged 50 to 85 Years. Arctic Therapeutics. 2025.
BibTeX
@misc{anon2025APhase,
title = {A Phase 2a Multi-site, Randomized, Double-blind, Dose Escalated, Placebo Controlled Biomarker Study to Determine the Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI (Mild Cognitive Impairment) or Mild Dementia Due to Alzheimer's Disease (AD) Aged 50 to 85 Years},
author = {Anonymous},
journal = {Arctic Therapeutics},
year = {2025},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
AbbVie 2015
Open access · US-GOV
A Study to Evaluate the Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of Multiple Doses of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment Due to Alzheimer's Disease
Biomed Industries, Inc. 2018
Open access · US-GOV
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of NA-831 in Alzheimer Patients With Mild Cognitive Impairment
IGC Pharma, LLC 2021
Open access · US-GOV
A Phase I Randomized Placebo Controlled MAD Study to Evaluate Safety and Tolerability of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease
Memory Pharmaceuticals 2007
Open access · US-GOV
A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of the Pharmacodynamics/Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Fixed Dosages of MEM 3454 (5 mg, 15 mg, and 50 mg) in Patients With Mild to Moderate Alzheimer's Disease
Shanghai Auzone Biological Technology Co., Ltd. 2025
Open access · US-GOV
A Prospective, International, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease
AstraZeneca 2016
Open access · US-GOV